Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir
356V Travatrelvir, an Inhibitor of SARS-CoV-2 Main...
Source: marketscreener.com
Genscript Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genscript Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genscript Inc Today - Breaking & Trending Today
GenScript Debuts AmMag™ Quatro to Revolutionize Automated Plasmid Maxi-Prep Purification
Latest innovative laboratory automation technology from GenScript is set to streamline maxi-scale plasmid purification, significantly reducing the manpower and time required to obtain high-quality,... | June 20, 2023
Source: marketscreener.com
Biodesix to Participate in Two Upcoming Investor Conferences in September
BOULDER, Colo.--(BUSINESS WIRE)--$BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:Morgan Stanley 20th Annual Gl...
Source: pharmiweb.com
Royal Philips: Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis
June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis
Source: finanznachrichten.de
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
01.06.2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference ...
Source: wallstreet-online.de